A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumors
NCT #
NCT05244551
Condition(s)
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
Molecular Target(s)
FGFR2/3
Drug Classification(s)
targeted
Agents(s)
ABSK061
Phase(s)
I
Mechanism of Action
ABSK061 inhibits FGFR2 and FGFR3. Inhibition of FGFR phosphorylation and signaling decreases cell viability. Selective inhibition avoids FGFR1 inhibition which potentially avoids side effects.
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from ABSK061
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.